RGIN.US Regenicin Inc.
- Market cap
- USD 15.3K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 4 quarters up to Sep 2023.
Is RGIN.US undervalued?
Graham numberThe Graham number of Regenicin Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Regenicin Inc. fundamental analysis
No fundamental analysis for Regenicin Inc. yet.
Regenicin Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Regenicin Inc.
Regenicin, Inc., a biotechnology company, develops regenerative cell therapies to restore the health of damaged tissues and organs. Its product includes Tiscela, a tissue-engineered skin graft that utilizes a patient's own skin cells to create living, regenerative skin for treating severe burns and chronic wounds. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartere…
Full company profileRegenicin Inc. financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 4 quarters up to Sep 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Regenicin Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | -601K | - |
| Operating Income | -997.76 | -726K | -1.22M | -780K | -976K | -540K | -737K | -511K | -842K | -601K | - |
| EBITDA | -3.60M | -242K | -234K | -1.07M | 4.67K | -540K | -737K | -511K | -842K | -656K | - |
| Net Income | -4.90M | 2.07K | 243K | -1.09M | -974K | -559K | -776K | -607K | -912K | -694K | - |
| EPS | -0.04 | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 | -0.01 | 0.00 | -0.01 | 0.00 | - |
| Balance Sheet | |||||||||||
| Total Assets | 96.3K | 2.89M | 1.48M | 360K | 87.8K | 56.4K | 5.32K | 4.14K | 4.61K | 15.5K | - |
| Total Liabilities | 4.24M | 4.40M | 2.25M | 1.83M | 2.53M | 3.06M | 3.73M | 4.29M | 5.17M | 5.61M | - |
| Shareholders' Equity | -4.14M | -1.52M | -768K | -1.47M | -2.44M | -3.00M | -3.73M | -4.29M | -5.16M | -5.60M | - |
| Cash & Short-term Investments | 22.5K | 492.00 | 1.36M | 226K | 27.2K | 11.2K | 5.32K | 4.14K | 4.61K | 15.5K | - |
| Total Debt | 865K | 807K | 270K | 175K | 175K | 213K | 455K | 578K | 603K | 643K | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -685K | -212K | -2.00M | -693K | -312K | -134K | -127K | -123K | -24.1K | -27.3K | - |
| Capital Expenditure | 0.00 | 0.00 | 10.0K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -685K | -212K | -2.01M | -693K | -312K | -134K | -127K | -123K | -24.1K | -27.3K | - |
| Ratios | |||||||||||
| ROA | -5,091.4% | 0.1% | 16.4% | -302.9% | -1,109.4% | -990.7% | -14,607.9% | -14,649.6% | -19,783.4% | -4,479.4% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
Regenicin Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
| 2016 | - | - | - |
| 2015 | - | - | - |
| 2014 | USD 70.8K | 0.00 | 3,421.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 34:1 on Aug 2, 2010.
Who owns Regenicin Inc.
Ownership data of Regenicin Inc. is not available yet.
Regenicin Inc. company profile
- Company name
- Regenicin Inc.
- Ticker
- RGIN.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3
- Fiscal year end
- September
- Address
- 3273 East Warm Springs Road, Las Vegas, NV, United States, 89120
- Phone
- 800 211 6348
- Website
- regenicin.com
About Regenicin Inc.
Regenicin, Inc., a biotechnology company, develops regenerative cell therapies to restore the health of damaged tissues and organs. Its product includes Tiscela, a tissue-engineered skin graft that utilizes a patient's own skin cells to create living, regenerative skin for treating severe burns and chronic wounds. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Las Vegas, Nevada.
Regenicin Inc. management
3- Mr. Randall E. McCoyChairman, CEO & President · born 1949
- Mr. John J. WeberCFO & Director · born 1950
- Dr. J. Roy Nelson Ph.D.Controller & Chief Science Officer · born 1948